The A-ZIPaF-1 mouse is lacking virtually all white adipose tissue. Like humans with extensive de®ciencies of adipose tissue, the A-ZIPaF-1 mice develop a severe form of insulin resistant diabetes. We have studied the physiology of the A-ZIPaF-1 mice. Their adaptation to fasting is notable for its rapidity and the use of torpor, a hibernation-like state, to minimize energy needs. Transplantation of adipose tissue reversed the metabolic manifestations in the mice, demonstrating that the lack of adipose tissue is the cause of the insulin resistance. Leptin replacement is not very effective in reversing the diabetes of the A-ZIPaF-1 mice, which contrasts with its ef®cacy in the aP2-SREBP-1c mouse.
Introduction to human lipodystrophyalipoatrophy
The lipodystrophiesalipoatrophies are a heterogeneous group of rare disorders, having in common a diminished amount of adipose tissue. 1, 2 Patients with these disorders exhibit a wide range in the distribution of fat loss, from generalized to partial to focal. The age of onset ranges from congenital through adulthood, and is often characteristic of the particular subtype of the disease. Patients with lipoatrophy, particularly those with greater degrees of fat de®ciency, develop type 2 diabetes. This is an intriguing contrast to obesity, in which an excess, rather than a de®ciency, of adipose tissue is associated with diabetes.
There are multiple causes of lipoatrophic diabetes, such as genetic, autoimmune and presumed toxic (eg HIV patients treated with protease inhibitors). Mechanisms both intrinsic and extrinsic to the adipocyte have been proposed, including destruction or inadequate production of adipocytes, abnormal nonadipocyte signals affecting metabolism, and intrinsic adipocyte abnormalities that alter their metabolic response. 3 A number of candidate genes have been excluded. 4 Recently, causative mutations, in the lamin AaC gene, were identi®ed for the Dunnigan variety of partial lipodystrophy. 5, 6 The chromosomal location (9q34) of the mutation in a subset of patients with congenital generalized lipodystrophy has also been identi®ed. 7 However, in most patients, the gene identities, mechanisms and even tissues of action remain a mystery.
Murine models of fat ablationalipoatrophy
We have developed a transgenic mouse, named AZIPaF-1, which has virtually no white adipose tissue (WAT). 8 These mice express, selectively in adipose tissue, a dominant negative protein that heterodimerizes with and inactivates members of the CaEBP and JUN families of B-ZIP transcription factors. The A-ZIPaF-1 phenotype strikingly resembles that of humans with severe lipoatrophic diabetes, such as congenital generalized lipodystrophy (Berardinelli ± Seip syndrome). Transgenic mice with similar, but less severe, phenotypes resulted from adipose expression of a modi®ed diphtheria toxin 9, 10 or a constitutively active SREBP-1c transcription factor. 11 A number of other mice with diminished amounts of fat have been reported. In some the reduced fat mass may be due to a nonspeci®c manifestation of a sick or undernourished animal, and not a primary adipose tissue phenotype. Here we will discuss the physiology of the A-ZIPaF-1 mice.
General phenotype of the A-ZIPaF-1 mice ( Table 1) 8 The A-ZIPaF-1 mice have virtually no visible WAT at any time during development. However, the mice are not completely WAT-free, since some adipocytes are visible upon microscopic examination. We estimate that the WAT mass is reduced by 99%. Extrahepatic triglyceride content is reduced 20-fold. In the AZIPaF-1 mouse, transgene expression is driven by the aP2a422 adipose fatty acid binding protein promoteraenhancer, which turns on during adipose differentiation later than markers such as PPARg-2 and CaEBPa. Thus, one might have expected that some adipocytes would be observed before the effects of the dominant negative protein would ablate the cells. However, we rarely observe lipid-containing cells, so the transgene must act before adipocytes can accumulate lipid.
At birth, brown adipose tissue (BAT) is found in the A-ZIPaF-1 mice in near-wild-type amounts. Histologically, this BAT appears normal and active. However, as the mice age, the BAT decreases in size and acquires a less eosinophilic staining pattern, with more lipid per cell. Expression of UCP-1, the marker of active BAT, is also very low. Thus the BAT undergoes accelerated, premature involution, becoming reduced in amount and inactive. Since the brown adipocytes express the transgene, it is likely that the BAT inactivation is the direct result of effects of the AZIPaF protein. We do not know why transgene expression results in a milder phenotype in the BAT, as compared to the WAT. One possible explanation is that the A-ZIPaF transgene is expressed at different levels in WAT and BAT. Another is that the transgene inactivates a slightly different set of endogenous B-ZIP transcription factors in WAT than in BAT.
The growth pattern of the A-ZIPaF-1 mice is complicated, with a number of different phases. Their size at birth is indistinguishable from wildtype littermates. However, the A-ZIPaF-1 mice immediately fall behind in growth, and by one week of age, they are only half the weight of their littermates. At weaning (3 ± 4 weeks of age), the A-ZIPaF-1 mice begin catch-up growth, and by 8 weeks of age they weigh as much as their littermates. We postulate that the poor growth while nursing is due to the high lipid content of milk, which the A-ZIPaF-1 pups cannot handle. The A-ZIPaF-1 mice continue to grow in adulthood, eventually surpassing their littermates in body weight. This continued growth may be due to insulin-like growth factor (IGF) effects of the very high insulin levels. Of note, the body weight underestimates the difference in lean body mass between AZIPaF-1 and wild-type mice, since the A-ZIPaF-1 body weight is essentially a lean body mass, while normal adult mice have 15% fat.
We routinely propagate the A-ZIPaF-1 mice by breeding hemizygous transgenic males with wildtype females. A-ZIPaF-1 mice are born at approximately the expected frequency, demonstrating no prenatal loss. However the mortality between birth and weaning can approach 50%. After weaning, the A-ZIPaF-1 mice have a much reduced, but still higher mortality than wild-type mice. No pups born to transgenic mothers have survived to weaning, possibly due to poor milk production. All experiments to date have been performed using hemizygous mice with a pure FVBaN background; at this time neither homozygous mice nor the effects of genetic background have been studied. Many aspects of the phenotype discussed below show a gender dimorphism, with males being more severely affected.
In addition to the lack of WAT and the abnormal BAT, the A-ZIPaF-1 mice have other anatomic abnormalities. The liver is greatly enlarged and engorged with lipid, with a centrilobular pattern to the steatosis. Quantitatively, the liver triglyceride content is up 11-fold. The kidneys, heart and spleen are enlarged. The mice are severely diabetic, with elevated serum glucose (3-fold) and insulin (50 ± 400-fold) levels, accompanied by polyuria, polydypsia and hyperphagia. The pattern is that of type 2 diabetes. In addition, the mice have elevated serum free fatty acids (FFA; 2-fold), and triglycerides (3 ± 5-fold) and reduced leptin levels (20-fold).
A-ZIPaF-1 mice respond to fasting by entering torpor 12 The total nonprotein energy stores in the A-ZIPaF-1 mice are reduced 10-fold, to 8.7 kcalamouse. This is Lipoatrophic diabetes ML Reitman and O Gavrilova less than the resting metabolic expenditure for one day ( 12 kcal), yet the A-ZIPaF-1 mice typically handle fasting for a day without problems. We therefore studied the response to fasting in detail. The AZIPaF-1 adaptation to fasting can be summarized brie¯y as a normal response to an abnormal situation: by 2 ± 4 h of fasting, the blood glucose is reduced to control levels, and thereafter is defended at this level. In contrast, after a 24 h fast, muscle and liver triglyceride and glycogen are all severely depleted, to much greater degree than in controls. Serum free (nonesteri®ed) fatty acids (FFA) and triglycerides also drop to very low levels, presumably re¯ecting the exhaustion of the tissue triglyceride stores. Normally, serum bhydroxybutyrate levels rise with fasting, re¯ecting conversion of FFA to ketone bodies, predominantly by liver, in order to keep the brain supplied with energy. However, b-hydroxybutyrate levels do not rise during fasting in A-ZIPaF-1 mice. This might be due to the paucity of FFA or to abnormal regulation of the conversion process. During fasting the blood urea nitrogen rises in the A-ZIPaF-1, but not control mice, indicating that the A-ZIPaF-1 mice catabolize protein in order to defend their glucose levels. In addition, the A-ZIPaF-1 mice adapt to fasting with a drop in metabolic rate, which is already evident after only a few hours of fasting. To summarize, in AZIPaF-1 mice a 24 h fast exhausts the carbohydrate and triglyceride stores, but the mice adapt by catabolism of muscle.
The A-ZIPaF-1 mice also use a remarkable method to conserve fuel during fasting. During a 24 h fast, AZIPaF-1 (but not control) mice enter a hibernationlike state called torpor. This saves the energy usually used to defend body temperature (one-third of resting metabolic rate at room temperature) and also reduces need much further. During torpor, the A-ZIPaF-1 mice develop a core body temperature of 2 C above ambient. Although not widely known, torpor is actually a normal response of mice to insuf®cient food in a quiet and suf®ciently cold environment. Leptin-de®cient obaob mice readily enter torpor with fasting, and leptin infusion prevents this. In contrast, neither leptin nor thyroid hormone prevented torpor in A-ZIPaF-1 mice. These data suggest that there are at least two signals for entry into torpor in mice, a low leptin level and another signal that is independent of leptin and thyroid hormone levels.
Reversal of diabetes in the A-ZIPaF-1 mice by transplantation of adipose tissue 13, 14 The A-ZIPaF-1 mice provide a way to rigorously test the role of WAT in the etiology of lipoatrophic diabetes. If the lack of fat is causing the diabetes, reconstitution with normal adipose tissue should reverse the metabolic derangement. We transplanted wild-type fat into A-ZIPaF-1 mice and indeed observed partial or complete reversal of the all aspects of the diabetic phenotype. The mice developed approximately normal glucose levels, dramatically lowered insulin levels, and improved liver and muscle insulin sensitivity. The hyperphagia, polyuria, hepatic steatosis and somatomegaly all improved. However, the reduction in triglyceride and FFA levels was modest. Donor fat taken from parametrial and subcutaneous sites was equally effective in reversing the phenotype. The bene®cial effects of transplantation were dose-dependent and required near-physiologic amounts of transplanted fat. These experiments demonstrate that the lack of WAT is causing the metabolic abnormalities. Additionally, fat transplantation is a new technique for studying adipose tissue physiology and the mechanisms of insulin resistance and type 2 diabetes.
Role of leptin in causing the phenotype of the A-ZIPaF-1 mice
Leptin's role in increasing insulin sensitivity has been demonstrated in a number of ways. Leptin treatment of obaob mice reverses their diabetes. Leptin treatment of normal rodents also provides more evidence for bene®cial effects of leptin on glucose homeostasis. 15, 16 In the aP2-SREBP-1c transgenic model of lipoatrophy, leptin treatment is remarkably effective at reversing the insulin resistance. 17 However, leptin is only marginally effective in reversing the diabetes of the A-ZIPaF-1 mice. 18 The difference between the A-ZIPaF-1 and aP2-SREBP-1c mice is probably due to the greater degree of fat loss in the A-ZIPaF-1, although transgene-speci®c effects or the different genetic backgrounds may contribute. The aP2-SREBP-1c mice have more residual adipose tissue. In these mice leptin appears to be limiting and its replacement reverses the diabetes. The A-ZIPaF-1 mice must be missing functions provided by adipose tissue, in addition to leptin secretion. One possibility is that adipose tissue's metabolic functions, affecting fatty acid and triglyceride metabolism are needed. Alternatively, adipose tissue could contribute via endocrine mechanisms, secreting hormones, either known or yet to be discovered. In conclusion, leptin de®ciency contributes to the insulin resistance of generalized lipoatrophy, but is neither the sole nor the major cause of insulin resistance in severe forms of this disease.
Perspectiveafuture directions
The full potential of the A-ZIPaF-1 mice is only beginning to be realized. One major question is the mechanism underlying the diabetes of the A-ZIPaF-1 mice. If tissue triglyceride is causing insulin resistance, how does it do so? Increased tissue (particularly muscle) triglyceride has also been proposed to cause the much more common obesity-associated type 2 diabetes. Thus mechanisms elucidated with lipoatrophic mice will supply ideas to be tested in other models.
Reconstitution of adipose tissue into the A-ZIPaF-1 mice by transplantation is a powerful tool. For example, the role of particular genes can be studied by using donor fat from genetically modi®ed mice. This approach is a possible alternative to tissue-speci®c recombination as a way to achieve adipose-speci®c knockouts. For example, leptin physiology can be examined by transplantation of WAT from obaob and dbadb mice into the A-ZIPaF-1 animals.
The A-ZIPaF-1 mice are also a wonderful system for devising and testing treatments for human lipoatrophic diabetes. Possible studies include drug trials and combinations of drugs with fat transplantation. The uses of lipoatrophic mice in elucidating the physiology and pathophysiology of adipose tissue are limited only by our imagination.
